Kiniksa Pharmaceuticals International (KNSA) Expected to Announce Earnings on Tuesday

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) is anticipated to release its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect Kiniksa Pharmaceuticals International to post earnings of $0.37 per share for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 8:30 AM ET.

Kiniksa Pharmaceuticals International Price Performance

Shares of KNSA stock opened at $45.37 on Tuesday. The business has a fifty day moving average of $42.29 and a 200 day moving average of $39.07. Kiniksa Pharmaceuticals International has a 1 year low of $18.25 and a 1 year high of $46.65. The firm has a market capitalization of $3.44 billion, a price-to-earnings ratio of 100.82 and a beta of 0.06.

Insiders Place Their Bets

In other news, COO Eben Tessari sold 12,048 shares of the business’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $41.56, for a total value of $500,714.88. Following the completion of the sale, the chief operating officer directly owned 16,666 shares in the company, valued at $692,638.96. The trade was a 41.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Barry D. Quart sold 20,129 shares of the stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $41.51, for a total value of $835,554.79. Following the transaction, the director owned 12,546 shares in the company, valued at $520,784.46. This trade represents a 61.60% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 123,823 shares of company stock worth $5,244,967. 53.48% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. EverSource Wealth Advisors LLC lifted its position in shares of Kiniksa Pharmaceuticals International by 140.4% in the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after acquiring an additional 532 shares in the last quarter. Osaic Holdings Inc. acquired a new stake in Kiniksa Pharmaceuticals International during the 2nd quarter worth $31,000. Smartleaf Asset Management LLC acquired a new position in Kiniksa Pharmaceuticals International during the fourth quarter worth about $36,000. CIBC Private Wealth Group LLC purchased a new stake in Kiniksa Pharmaceuticals International during the 4th quarter valued at about $41,000. Finally, Quantbot Technologies LP purchased a new stake in Kiniksa Pharmaceuticals International during the 2nd quarter valued at about $43,000. 53.95% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

KNSA has been the subject of a number of research reports. Wedbush lifted their target price on Kiniksa Pharmaceuticals International from $48.00 to $50.00 and gave the stock an “outperform” rating in a report on Tuesday, January 13th. Wall Street Zen downgraded shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a report on Sunday, November 2nd. Zacks Research cut shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 13th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Thursday, January 22nd. Finally, The Goldman Sachs Group increased their price target on Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Kiniksa Pharmaceuticals International presently has a consensus rating of “Moderate Buy” and a consensus price target of $52.33.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.